Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385941 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2DYRK1AKDM4EDYRK1BALDH1A1 | |
| SCHEMBL29385696 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2DYRK1ADYRK1BALDH1A1AURKA | |
| SCHEMBL16668494 | 0.75 | SMN1; SMN2 (0.39) | SMN1; SMN2DYRK1ADYRK1BALDH1A1AURKA | |
| SCHEMBL1500697 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2DYRK1AKDM4EDYRK1BALDH1A1 | |
| SCHEMBL23360456 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2DYRK1ADYRK1BALDH1A1AURKA | |
| SCHEMBL29862595 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2DYRK1ADYRK1BALDH1A1AURKA | |
| SCHEMBL31378796 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2DYRK1AKDM4EDYRK1BALDH1A1 | |
| SCHEMBL24674192 | 0.72 | DYRK1B (0.41) | SMN1; SMN2DYRK1ADYRK1BALDH1A1AURKA | |
| SCHEMBL29427703 | 0.72 | DYRK1B (0.41) | SMN1; SMN2DYRK1ADYRK1BALDH1A1AURKA | |
| SCHEMBL20589976 | 0.71 | KMT2A (0.44) | SMN1; SMN2DYRK1ADYRK1BALDH1A1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-11-14 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117321037-A | GCN2 and PERK kinase inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4247795-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220274934-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-06-30 | — | — | US | disclosed |
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
| US-9434700-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 2016-09-06 | — | — | US | disclosed |
| US-9434700-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 2016-09-06 | — | — | US | disclosed |
| US-9434700-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 2016-09-06 | — | — | US | disclosed |
| EP-3060560-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | Blueprint Medicines Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061572-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015061572-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | XBP1, HSPA5, ERN2 | SMN1; SMN2 52/4885DYRK1A 2258/4885KDM4E 4000/4885 |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | SMN1; SMN2 3899/4885DYRK1A 2078/4885KDM4E 976/4885 |
| US-20240376058-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | SMN1; SMN2 670/4885DYRK1A 2713/4885KDM4E 3828/4885 |
| US-20220274934-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | EIF2AK4, GCN1, EEF2K | SMN1; SMN2 670/4885DYRK1A 2713/4885KDM4E 3828/4885 |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | SMN1; SMN2 3899/4885DYRK1A 2078/4885KDM4E 976/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | SMN1; SMN2 538/4885DYRK1A 881/4885KDM4E 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.